Home » Stocks » KIN

Kindred Biosciences, Inc. (KIN)

Stock Price: $9.08 USD -0.03 (-0.33%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
Pre-market: $9.05 -0.03 (-0.33%) Jul 30, 5:50 AM
Market Cap 412.57M
Revenue (ttm) 43.96M
Net Income (ttm) -8.78M
Shares Out 41.09M
EPS (ttm) -0.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $9.08
Previous Close $9.11
Change ($) -0.03
Change (%) -0.33%
Day's Open 9.12
Day's Range 9.05 - 9.12
Day's Volume 940,150
52-Week Range 3.20 - 9.28

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK, July 21, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or...

Other stocks mentioned: CVA, RIVE, SWN
1 week ago - PRNewsWire

NEW YORK, June 22, 2021 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whe...

Other stocks mentioned: DCRC, ROCR, SVOK
1 month ago - PRNewsWire

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Kindred Bioscience...

Other stocks mentioned: ELAN
1 month ago - Business Wire

NEW YORK, June 16, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action...

1 month ago - PRNewsWire

The pet therapeutics pioneer is being scooped up by a global animal health leader.

1 month ago - The Motley Fool

Elanco Animal Health Inc (NYSE: ELAN) said on Wednesday it will acquire Kindred Biosciences Inc (NASDAQ: KIN) for roughly $440 million (£312 million) to expand its footprint in the pet health industry. ...

Other stocks mentioned: ELAN
1 month ago - Invezz

Kindred Biosciences, Inc. (NASDAQ: KIN), Aprea Therapeutics, Inc. (NASDAQ: APRE), Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) and Inhibikase Therapeutics, Inc. (NASDAQ: IKT) are among the biggest bio...

Other stocks mentioned: APRE, CATB, IKT
1 month ago - Benzinga

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Kindred Biosciences, Inc. (NASDAQ: KIN) to Elanco Animal Health Incorporated for $9.2...

1 month ago - Business Wire

Elanco Animal Health Incorporated (NYSE: ELAN) has agreed to acquire Kindred Biosciences Inc (NASDAQ: KIN) for $9.25 per share, or approximately $440 million. The price represents a premium of 52% based...

Other stocks mentioned: ELAN
1 month ago - Benzinga

Kindred Bio (KIN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in t...

1 month ago - Zacks Investment Research

SAN FRANCISCO, June 2, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from ...

1 month ago - PRNewsWire

SAN FRANCISCO, May 25, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the Stifel 2021 Virtua...

2 months ago - PRNewsWire

Shares of Kindred Biosciences (NASDAQ:KIN) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share rose 46.67% year over year to ($0.24), which were in line with the e...

2 months ago - Benzinga

SAN FRANCISCO, May 11, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for ...

2 months ago - PRNewsWire

SAN FRANCISCO, May 3, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its first quarter 2021 fin...

2 months ago - PRNewsWire

Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

SAN FRANCISCO, April 28, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that the United Stat...

3 months ago - PRNewsWire

SAN FRANCISCO, April 20, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today unveiled positive results in a...

3 months ago - PRNewsWire

Point72 Asset Management leader Steven Cohen (Trades, Portfolio) disclosed a 9.31% stake in Kindred Biosciences Inc. (NASDAQ:KIN) earlier this week.

3 months ago - GuruFocus

Kindred Bio (KIN) delivered earnings and revenue surprises of 15.15% and -0.94%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

SAN FRANCISCO, March 16, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results fo...

4 months ago - PRNewsWire

Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

SAN FRANCISCO, Feb. 25, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has submitted...

5 months ago - PRNewsWire

SAN FRANCISCO, Feb. 16, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the BofA Securities A...

5 months ago - PRNewsWire

SAN FRANCISCO, Feb. 9, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has appointed ...

5 months ago - PRNewsWire

SAN FRANCISCO, Dec. 21, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from...

7 months ago - PRNewsWire

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today announced an agreement with Kindred Biosciences (NASDAQ: KIN) to acquire exclusive global rights to KIND-030, a fi...

Other stocks mentioned: ELAN
7 months ago - Business Wire

SAN FRANCISCO, Dec. 2, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Dr. Richard Chin,...

7 months ago - PRNewsWire

Kindred Biosciences, Inc. (KIN) CEO Richard Chin on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Kindred Bio (KIN) delivered earnings and revenue surprises of 0.00% and 82.98%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

SAN FRANCISCO, Nov. 9, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for ...

8 months ago - PRNewsWire

Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

SAN FRANCISCO, Oct. 28, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its third quarter 2020 f...

9 months ago - PRNewsWire

SAN FRANCISCO, Sept. 16, 2020 /PRNewswire/ -- Kindred Biosciences, Inc.

10 months ago - PRNewsWire

SAN FRANCISCO, Sept. 9, 2020 /PRNewswire/ -- Kindred Biosciences, Inc.

10 months ago - PRNewsWire

Two Sample Breakout Stocks for Week 36 with better than 10% short-term upside potential. Now up an average 183.6% YTD.

Other stocks mentioned: AAPL, CVX, EXK, HD, JNJ, MRK, PFE ...
10 months ago - Seeking Alpha

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Other stocks mentioned: AWR, CLRB, CVEO, POR
11 months ago - Zacks Investment Research

Kindred Biosciences, Inc.'s (KIN) CEO Richard Chin on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Kindred Bio (KIN) delivered earnings and revenue surprises of 333.33% and 100.19%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Kindred Bio (KIN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 year ago - Zacks Investment Research

Investors need to pay close attention to Kindred Biosciences (KIN) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

SAN FRANCISCO, June 8, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced a plan to enhance its ...

1 year ago - PRNewsWire

Kindred Biosciences, Inc. (KIN) CEO Richard Chin on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Kindred Biosciences, Inc. (KIN) CEO Richard Chin on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Kindred Bio (KIN) delivered earnings and revenue surprises of -5.26% and -3.38%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Kindred Biosciences, Inc. (KIN) CEO Richard Chin on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About KIN

Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, engages in developing therapies for pets. Its product pipeline focuses on biologics for a range of indications primarily in dogs and cats. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats; and Zimeta, a dipyrone injection for the control of fever in horses. It also develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-032, a monoclonal antibody targeting interleukin-4 (IL-4) rec... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Dec 12, 2013
CEO
Richard Chin
Employees
63
Stock Exchange
NASDAQ
Ticker Symbol
KIN
Full Company Profile

Financial Performance

In 2020, KIN's revenue was $42.16 million, an increase of 890.70% compared to the previous year's $4.26 million. Losses were -$21.80 million, -64.50% less than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for KIN stock is "Buy." The 12-month stock price forecast is 10.50, which is an increase of 15.64% from the latest price.

Price Target
$10.50
(15.64% upside)
Analyst Consensus: Buy